Synergistic effects of geldanamycin and antitumor drugs

Yaoxue Xuebao

Volumn 36, Issue 8, 2001, Pages 569-574

  Liao, Zhi Yong ^a   Zhang, Sheng Hua ^a   Zhen, Yong Su ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Biochemical modulator; Cisplatin; Combination cancer chemotherapy biograp; Geldanamycin; Mitomycin C

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CISPLATIN; GELDANAMYCIN; MITOMYCIN; QUINONE DERIVATIVE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; LIVER CELL CARCINOMA; LIVER TUMOR; MOUSE; PATHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DRUG SYNERGISM; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MITOMYCIN; NEOPLASM TRANSPLANTATION; QUINONES; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0042337311     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. DeBoer C, Meulman PA, Wnuk RJ, et al. Geldanamycin, a new antibiotic [J]. J Antibiot, 1970, 23(9):442-447.
2. Whitesell L, Mimnaugh EG, De CB, et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation [J]. Proc Natl Acad Sci USA, 1994, 91(18):8324-8328.
3. Pearl LH, Prodromou C. Structure and in vivo function of Hsp90 [J]. CWT Opin Struct Biol, 2000, 10(1):46-51.
4. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity [J]. Invest New Drugs, 1999, 17(1): 361-373.
5. Gabai VL, Mosina VA, Budagova KR, et al. Spontaneous overexpression of heat shock protein in Ehrlisch ascites carcinoma cells during in vivo growth [J]. Biochem Mol Int, 1995, 35(1):95-102.
6. Ferrarini M, Heltai S, Zocchi MR, et al. Unusual expression and localization of heat-shock proteins in human tumor cells [J]. Int J Cancer, 1992, 51(4):613-619.
7. Conroy SE, Latchman DS. Do heat shock proteins have a role in breast cancer [J]? Br J Cancer, 1996, 74(5):717-721.
8. Yano M, Naito Z, Tanaka S, et al. Expression and roles of heat shock proteins in human breast cancer [J]. Jpn J Cancer Res, 1996, 87(9):908-915.
9. Csermely P, Schnaider T, Soti C, et al. The 90-kDa molecular chaperone family: Structure, function, and clinical applications. A comprehensive review [J]. Pharmacol Ther, 1998, 79(2):129-168.
10. Scheibel T, Buchner J. The Hsp90 complex-a super-chaperone machine as a novel drug target [J]. Biochem Pharmacol, 1998, 56(6):675-682.
11. Carmichael J, DeGraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semi-automated colorimetric assay: assessment of chemosensitivity testing [J]. Cancer Res, 1987, 47(4):936-942.
12. Cao SS, Zhen YS. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B [J]. Cancer Chemother Pharmacol, 1989, 24(3):181-186.
13. Vargas-Roig LM, Gago FE, Tello O, et al. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy [J]. Int J Cancer, 1998, 79(5):468-475.
14. Khan SM, Oliver RH, Dauffenbach LM, et al. Depletion of Raf-1 protooncogene by geldanamycin causes apoptosis in human luteinized granulosa cells [J]. Fertil Steril, 2000, 74 (2):359-365.
15. Tikhomirov O, Carpenter G. Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation [J]. J Biol Chem, 2000, 275(34):26625-26631.
16. An WG, Schnur RC, Neckers L, et al. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity [J]. Cancer Chemother Pharmacol, 1997, 40(1):60-64.
17. McIlwrath AJ, Brunton VG, Brown R. Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells [J]. Cancer Chemother Pharmacol, 1996, 37 (5):423-428.
18. Kim HR, Lee CH, Choi YH, et al. Geldanamycin induces cell cycle arrest in K562 erythroleukemic cells [J]. IUBMB Life, 1999, 48(4):425-428.
19. Lopez-Maderuelo MD, Fernandez-Renart M, Moratilla C, et al. Opposite effects of the Hsp90 inhibitor Geldanamycin: induction of apoptosis in PC12, and differentiation in N2A cells [J]. FEBS Lett, 2001, 490(1-2):23-27.
20. Zhen YS. Antitumor biochemical modulators of natural origin [J]. Bull Chin Cancer (in Chinese), 1999, 8(10):459-460.
21. Su J, Zhen YS, Qi CQ, et al. A fungus-derived novel nucleoside transport inhibitor potentiates the activity of antitumor drugs [J]. Acta Pharm Sin (in Chinese), 1994, 29(9):656-661.
22. Zhen YS, Taniki T, Weber G. Azidothymidine and dipyridamole as biochemical response modifier: Synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells [J]. Oncol Res, 1992, 4(2):73 -78.
23. Zhang L, Lau YK, Xia W, et al. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel [J]. Clin Cancer Res, 1999, 5 (2):343-353.
24. Zhang L, Hung MC. Sensitization of HER-2/neuoverexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin [J]. Oncogene, 1996, 12(3):571-576.
25. Jiang XF, Zhen YS. Reversal of multidrug resistance by emodin in cancer cells [J]. Acta Pharm Sin (in Chinese), 1999, 34(3):164-167.
26. Mandler R, Dadachova E, Brechbiel JK, et al. Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immuno conjugate [J]. Bioorg Med Chem Lett, 2000, 10(10):1025-1028.